Becton Dickinson to invest $19B in US for tariff relief
What's the deal? Becton Dickinson has committed to invest $19bn in the United States under an agreement with the Trump administration that offers protection against future tariffs. The medical device maker is the first major US player in the sector to reach such a deal.
Where the money goes: The group will direct the investment toward its production capabilities, operations, and supply chain, including $3bn earmarked for strategic manufacturing sites. More than $1bn of that $3bn will go to Nebraska.
Becton Dickinson plans to increase its US production of essential medical consumables by roughly 5bn units per year, lifting the share sourced domestically to about 80%. It also plans to manufacture all needles for the US market in the United States, using domestically produced steel.
What's in it for the company? In return, certain products and inputs could qualify for reduced future tariffs under Section 232. The group has not quantified the agreement's financial impact, as the rates, covered products, and final schedule are still undetermined.
Why now? The agreement fits the Trump administration's strategy of using tariffs to encourage reshoring in the health care sector. In January, Becton Dickinson announced a $110m investment in Columbus, Nebraska, to expand production of prefilled syringes and cannulas and create about 120 jobs.
The signal: As the first major medical device maker to strike a tariff-protection deal, Becton Dickinson sets a template others in the sector may follow.
Read more: in.marketscreener.com
Image credit: MDGovpics
